Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Non-Current Debt: 2019-2025

  • Burning Rock Biotech's Non-Current Debt was N/A to $34.9 billion in Q2 2022 from the same period last year, while for Jun 2022 it was $34.9 billion, marking a year-over-year change of. This contributed to the annual value of $35.7 billion for FY2021, which is N/A change from last year.
  • Per Burning Rock Biotech's latest filing, its Non-Current Debt stood at $34.9 billion for Q2 2022, which was down 3.04% from $36.0 billion recorded in Q4 2021.
  • Burning Rock Biotech's 5-year Non-Current Debt high stood at $36.0 billion for Q4 2021, and its period low was $34.9 billion during Q2 2022.
  • Its 2-year average for Non-Current Debt is $35.4 billion, with a median of $35.4 billion in 2021.